Clinical review report: Brexpiprazole (Rexulti) (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults
Brexpiprazole is an atypical antipsychotic drug indicated for the treatment of schizophrenia in adults. The product monograph states that the efficacy of brexpiprazole is thought to be mediated through partial agonist activity at serotonergic 5-HT1A and dopaminergic D2 receptors, and antagonist acti...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa, Ontario]
Canadian Agency for Drugs and Technologies in Health
2017, December 2017
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Brexpiprazole is an atypical antipsychotic drug indicated for the treatment of schizophrenia in adults. The product monograph states that the efficacy of brexpiprazole is thought to be mediated through partial agonist activity at serotonergic 5-HT1A and dopaminergic D2 receptors, and antagonist activity at serotonergic 5-HT2A receptors. The recommended dosage is 2 mg to 4 mg once daily. The product monograph recommends a starting dosage of 1 mg per day on days 1 to 4, titrated to 2 mg once daily on days 5 to 7, and then to 4 mg on day 8, based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg for most patients. The manufacturer has requested that brexpiprazole be reimbursed in accordance with the Health Canada-approved indication (i.e., for the treatment of schizophrenia in adults) |
|---|---|
| Item Description: | "Version: final with redactions." |
| Physical Description: | 1 PDF file (155 pages) illustrations |